Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 3/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6662068 | 0.75 | PSIP1 (0.47) | PSIP1PGRHPGDCYP3A4CYP2C9 | |
| SCHEMBL31047810 | 0.72 | PSIP1 (0.51) | PSIP1PGRHPGDCYP3A4CYP2C9 | |
| SCHEMBL6199133 | 0.72 | KMT2A (0.34) | — | |
| SCHEMBL10519626 | 0.71 | PSIP1 (0.41) | PSIP1PGRHPGDLMNAHSD17B10 | |
| SCHEMBL5846557 | 0.71 | CYP3A4 (0.42) | HPGDCYP3A4ALDH1A1 | |
| SCHEMBL7688191 | 0.69 | PGR (0.40) | PSIP1PGRHPGDLMNAHSD17B10 | |
| SCHEMBL7017288 | 0.69 | NEU3 (0.35) | PGRARMAPT | |
| SCHEMBL6663333 | 0.68 | PSIP1 (0.50) | PSIP1PGRHPGDLMNAHSD17B10 | |
| SCHEMBL30017045 | 0.67 | CYP3A4 (0.42) | HPGDCYP3A4ALDH1A1 | |
| SCHEMBL10938599 | 0.67 | PPOX (0.32) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030017948-A1 | Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-23 | — | — | US | disclosed |
| EP-1244615-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | Bayer Aktiengesellschaft (DE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047873-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017948-A1 | Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates | DDT, PFAS, DAO | PSIP1 1439/4885PGR 4770/4885HPGD 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.